Monoamine depletion by reuptake inhibitors

Drug, Healthcare and Patient Safety

Volumn 3, Issue 1, 2011, Pages 69-77

  Hinz, Marty ^a   Stein, Alvin ^b   Uncini, Thomas ^c  

^a Neuroresearch clinics inc   (United States)

^b Stein Orthopedic Associates   (United States)

^c DBS Labs inc   (United States)

Author keywords

Depletion; Dopamine; Relapse; Reuptake inhibitor; Serotonin; Tachyphylaxis

Indexed keywords

5 HYDROXYTRYPTOPHAN; ADRENALIN; AMINO ACID; ASCORBIC ACID; CITALOPRAM; CITRATE CALCIUM; DOPAMINE; FOLIC ACID; NORADRENALIN; ORGANIC CATION TRANSPORTER; PHENTERMINE; PLACEBO; PYRIDOXINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN; TYROSINE;

ARTICLE; ATTENTION DEFICIT DISORDER; BARIATRICS; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MECHANISM; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOAMINE METABOLISM; MORNING DOSAGE; PILOT STUDY; RETROSPECTIVE STUDY; SCORING SYSTEM; TACHYPHYLAXIS; THEORETICAL MODEL;

EID: 84855290767     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/dhps.s24798     Document Type: Article

References (37)

1. Frank R, Glied S. Better but Now Well: Mental Health Policy in the United States since 1950. Baltimore, MD: Johns Hopkins University Press; 2006.
2. Mantzoros C. Nutrition and Metabolism: Underlying Mechanisms and Clinical Consequences. Totowa, NJ: Humana Press; 2009.
3. Dextroamphetamine and amphetamine (CII) prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011522s040lbl.pdf. Accessed July 30, 2011.
4. Fluvoxetine prescribing information. Available from: http://www. luvoxcr.com/LUVOX-CR-PI.pdf. Accessed July 30, 2011.
5. Bupropion prescribing information. Available from: http://us.gsk.com/ products/assets/us_zyban.pdf. Accessed July 30, 2011.
6. Merriam-Webster online dictionary http://www.merriam-webster.com/ medical/tachyphylaxis?show=0&t=1312033095. Accessed July 30, 2011.
7. Hinz M. Depression. In: Kohlstadt I, editor. Food and Nutrients in Disease Management. Boca Raton, FL: CRC Press; 2009.
8. Hinz M, Stein A, Uncini T. Treatment of attention defcit hyperac-tivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation. Neuropsychiatr Dis Treat. 2011;7:31-38.
9. McGrath P, Stewart J, Quitkin F. Predictors of relapse in a prospective study of fuoxetine treatment of major depression. Am J Psychiatry. 2006;163:1542-1548.
10. Michelson D, Buitelaar J, Danckaerts M. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double blind, placebo controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43:896-904.
11. Hinz M, Stein A, Uncini T. The dual-gate lumen model of renal mono-amine transport Neuropsychiatr Dis Treat. 2010;6:387-392.
12. Hinz M, Stein A, Trachte G, Uncini T. Neurotransmitter testing of the urine: A comprehensive analysis. Open Access Journal of Urology. 2010;2:177-183.
13. Hinz M, Stein A, Uncini T. Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine. Open Access Journal of Urology. 2011;3:19-24.
14. Hinz M, Stein A, Uncini T. Amino acid management of Parkinson's disease: A case study. Int J Gen Med. 2011;4:1-10.
15. Hinz M, Stein A, Uncini T. Validity of urinary monoamine assay sales under the spot baseline urinary neurotransmitter testing marketing model". Int J Nephrol Renovasc Dis. 2011;4:101-113.
16. Hinz M, Stein A, Uncini T. APRESS: apical regulatory super system, serotonin, and dopamine interaction. Neuropsychiatr Dis Treat. 2011;7:457-463.
17. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 1994 (American Psychiatric Association) p. 372
18. Delgado P, Miller H, Salomon R, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fuoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry. 1999;46:212-220.
19. Page M, Detke M, Dalvi A, et al. Serotonergic mediation of the effects of fuoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology. 1999;147:162-167.
20. Trachte G, Uncini T, Hinz M. Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population. Neuropsychiatr Dis Treat. 2009;5:227-235.
21. Stein A, Hinz M, Uncini T. Amino acid responsive Crohn's disease, a case study. Clin Exp Gastroenterol. 2010:3:171-177.
22. Hinz M, Stein A, Uncini T. A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole. Neu-ropsychiatr Dis Treat. 2010;6:741-747.
23. Alvarez J, Sanceaume M, Advenier C, et al. Differential changes in brain and platelet 5-HT concentrations after steady-state achievement and repeated administration of antidepressant drugs in mice. Eur Neu-ropsychopharmacol. 1999;10:31-36.
24. Dalton S, Johansen C, Mellemkjar L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding. Arch Intern Med. 2003;163:59-64.
25. Wagner A, Montero D, Martensson B, et al. Effects of fuoxetine treatment of platelet 3H-imipramine binding, 5-HT uptake and 5-HT content in major depressive disorder. J Affect Disord. 1990;20:101-113.
26. Yuan Y, Tsoi K, Hunt R. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: Confusion or confounding? Am J Med. 2006;119:719-727.
27. Meier C, Schlienger R, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing frst-time acute myocardial infarction. Br J Clin Pharmacol. 2001;52:179-184.
28. Fuller R, Wong D. Serotonin uptake and serotonin uptake inhibition. Ann N Y Acad Sci. 1990;600:68-78.
29. de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol. 2000;50:43-47.
30. Layton D, Clark D, Pearce D, Shakir SA. Is there an association between reuptake inhibitors and the risk of abnormal bleeding? Eur J Clin Pharmacol. 2001;57:167-176.
31. Kalia M, O'Callaghan J, Miller D, et al. Comparative study of fuox-etine, sibutramine, sertraline and dexfenfuramine on the morphology of serotonergic nerve terminals using serotonin immunohistochemistry. Brain Res. 2000;858:92-105.
32. Cooney C, Wise C, Poirier LA, Ali SF. Methamphetamine treatment affects blood and liver S-adenosylmethionine (SAM) in mice: correlation with dopamine depletion in the striatum. Ann NY Acad Sci. 1998;844:191-200.
33. Stenfors C, Yu H, Ross S. Pharmacological characterisation of the decrease in 5-HT synthesis in the mouse brain evoked by the selective serotonin re-uptake inhibitor citalopram. Arch Pharmacol. 2001;363:222-232.
34. Galun E, Flugelman M, Glickson M, et al. Failure of long-term digitali-zation to prevent rapid ventricular response in patients with paroxysmal atrial fbrillation. Chest. 1991;99:1038-1040.
35. National Institute of Drug Abuse. The neurobiology of ecstasy. Slides 9-11. Available from: http://www.nida.nih.gov/pubs/teaching/Teaching4/Teaching.html. Accessed July 29, 2011.
36. Black K, Shea C, Dursun S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci. 2000;25:255-261.
37. Forbes. Available from: http://www.forbes.com/feeds/ap/2011/07/25/general-health-care-us-generics-bonanza_8582330.html. Accessed July 31, 2011.